CD64-directed microtubule associated protein tau kills leukemic blasts  ex vivo

Radoslav Mladenov; Dmitrij Hristodorov; Christian Cremer; Gerrit Gresch; Elena Grieger; Lea Schenke; Diana Klose; Manal Amoury; Mira Woitok; Edgar Jost; Tim H. Brümmendorf; Rolf Fendel; Rainer Fischer; Christoph Stein; Theo Thepen; Stefan Barth

doi:10.18632/oncotarget.11568

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

CD64-directed microtubule associated protein tau kills leukemic blasts ex vivo

Radoslav Mladenov, Dmitrij Hristodorov, Christian Cremer, Gerrit Gresch, Elena Grieger, Lea Schenke, Diana Klose, Manal Amoury, Mira Woitok, Edgar Jost, Tim H. Brümmendorf, Rolf Fendel, Rainer Fischer, Christoph Stein, Theo Thepen and Stefan Barth _

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2016; 7:67166-67174. https://doi.org/10.18632/oncotarget.11568

Metrics: PDF 2301 views | HTML 4309 views | ?

Abstract

Radoslav Mladenov1, Dmitrij Hristodorov1, Christian Cremer2, Gerrit Gresch2, Elena Grieger2, Lea Schenke2, Diana Klose1, Manal Amoury1, Mira Woitok1, Edgar Jost3, Tim H. Brümmendorf3, Rolf Fendel1,2, Rainer Fischer2,4, Christoph Stein1,2, Theo Thepen1,*, Stefan Barth1,2,5,*

1Fraunhofer Institute for Molecular Biology and Applied Ecology, Aachen, Germany

2Department of Experimental Medicine and Immunotherapy, Institute of Applied Medical Engineering, University Hospital, RWTH Aachen University, Aachen, Germany

3Department of Haematology and Oncology (Internal Medicine IV), RWTH Aachen University Hospital, Aachen, Germany

4Institute of Molecular Biotechnology (Biology VII), RWTH Aachen University, Aachen, Germany

5South African Research Chair in Cancer Biotechnology, Institute of Infectious Disease and Molecular Medicine (IDM), Department of Integrative Biomedical Sciences, Faculty of Health Sciences, University of Cape Town, South Africa

*Shared authorship

Correspondence to:

Stefan Barth, email: [email protected]

Keywords: immunotherapy, myeloid leukemia, cytolytic fusion proteins, Fc-gamma receptor (CD64), microtubule associated protein tau (MAP)

Received: March 14, 2016 Accepted: August 11, 2016 Published: August 24, 2016

ABSTRACT

Fc gamma receptor I (FcγRI, CD64) is a well-known target antigen for passive immunotherapy against acute myeloid leukemia and chronic myelomonocytic leukemia. We recently reported the preclinical immunotherapeutic potential of microtubule associated protein tau (MAP) against a variety of cancer types including breast carcinoma and Hodgkin’s lymphoma. Here we demonstrate that the CD64-directed human cytolytic fusion protein H22(scFv)-MAP kills ex vivo 15–50% of CD64⁺ leukemic blasts derived from seven myeloid leukemia patients. Furthermore, in contrast to the nonspecific cytostatic agent paclitaxel, H22(scFv)-MAP showed no cytotoxicity towards healthy CD64⁺ PBMC-derived cells and macrophages. The targeted delivery of this microtubule stabilizing agent therefore offers a promising new strategy for specific treatment of CD64⁺ leukemia.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 11568

Publication Alerts

Research Papers:

CD64-directed microtubule associated protein tau kills leukemic blasts ex vivo

Abstract